Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
stocks
Why Guzman and Reece's share reversals have a lot in common
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,477.30 | 20.70 | -0.24% |
CAC 40 | 8,126.26 | 75.19 | 0.93% |
DAX 40 | 22,701.96 | 291.69 | 1.30% |
Dow JONES (US) | 43,621.16 | 159.95 | 0.37% |
FTSE 100 | 8,708.74 | 40.07 | 0.46% |
HKSE | 23,787.93 | 753.91 | 3.27% |
NASDAQ | 19,026.39 | 260.54 | -1.35% |
Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
S&P 500 | 5,955.25 | 0.00 | 0.00% |
S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
SSE Composite Index | 3,380.21 | 34.17 | 1.02% |